Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $31,780.00 in Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,270 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $14.00, for a total transaction of $31,780.00. Following the completion of the transaction, the chief financial officer owned 90,180 shares in the company, valued at approximately $1,262,520. The trade was a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.00, for a total transaction of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total transaction of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $12.00, for a total transaction of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total transaction of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total transaction of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Stock Up 1.6%

NASDAQ:DRTS opened at $12.98 on Friday. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average of $10.27 and a 200-day moving average of $8.13. The firm has a market capitalization of $1.17 billion, a PE ratio of -19.37 and a beta of 1.17. Alpha Tau Medical Ltd. has a 52 week low of $2.87 and a 52 week high of $14.11.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Analysts predict that Alpha Tau Medical Ltd. will post -0.67 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Envestnet Asset Management Inc. acquired a new position in shares of Alpha Tau Medical during the third quarter valued at $62,000. Bank of America Corp DE lifted its holdings in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after purchasing an additional 21,677 shares during the period. Millennium Management LLC bought a new position in Alpha Tau Medical in the 3rd quarter valued at about $170,000. Mariner LLC grew its position in Alpha Tau Medical by 185.8% in the 3rd quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after buying an additional 80,129 shares in the last quarter. Finally, Apella Capital LLC acquired a new position in Alpha Tau Medical during the 4th quarter valued at about $1,892,000. Institutional investors own 2.65% of the company’s stock.

Analyst Upgrades and Downgrades

DRTS has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Barclays lifted their price objective on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Alpha Tau Medical in a research note on Tuesday, June 2nd. Zacks Research cut shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 1st. Finally, LADENBURG THALM/SH SH upped their target price on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $12.60.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.